BioCopy Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
39
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$11.4M
- Investors
-
3
BioCopy General Information
Description
Developer of a biomolecule copying technology designed for the production and replication of microarrays. The company's technology provides a shortcut to navigate the complexity of the immune system for future tumor and autoimmune therapy, which can be applied in diagnostics, vaccine development, as well as lead and hit screening, enabling clients to copy biomolecules analogous to a photocopier.
Contact Information
Website
www.biocopy.comCorporate Office
- Stücki Park
- Hochbergerstrasse 60 Floor
- 4057 Basel
- Switzerland
Corporate Office
- Stücki Park
- Hochbergerstrasse 60 Floor
- 4057 Basel
- Switzerland
BioCopy Timeline
BioCopy Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC (Series A) | 01-May-2026 | $11.4M | Completed | Generating Revenue | ||
| 5. Seed Round | 15-Dec-2025 | Completed | Generating Revenue | |||
| 4. Angel (individual) | 27-Aug-2021 | Cancelled | Generating Revenue | |||
| 3. Grant | 01-Jun-2018 | Completed | Startup | |||
| 2. Angel (individual) | 01-Jan-2016 | $2.18M | $2.18M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2016 | Completed | Startup |
BioCopy Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
BioCopy Patents
BioCopy Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4837921-A1 | Antigen binding proteins specifically binding mage-a3 | Pending | 09-May-2025 | ||
| WO-2026234298-A1 | Antigen binding proteins specifically binding mage-a3 | Pending | 09-May-2025 | ||
| EP-4831636-A1 | Improved immunopeptidome method to identify neoepitopes for cancer immunotherapy and neoepitopes as identified | Pending | 25-Apr-2025 | ||
| WO-2026224094-A1 | Improved immunopeptidome method to identify neoepitopes for cancer immunotherapy and neoepitopes as identified | Pending | 25-Apr-2025 | ||
| EP-4810517-A1 | Antigen binding proteins specifically binding mage-a4 | Pending | 21-Mar-2025 | C07K16/30 |
BioCopy Signals
BioCopy Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Haute Capital Partners | PE/Buyout | Minority | ||
| EASME - EU Executive Agency for SMEs | Corporation | |||
| The University of Freiburg | University |
BioCopy Acquisitions (1)
BioCopy’s most recent deal was a Merger/Acquisition with Perspix Biotech. The deal was made on 09-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Perspix Biotech | 09-Apr-2024 | Merger/Acquisition | Biotechnology |
BioCopy FAQs
-
When was BioCopy founded?
BioCopy was founded in 2016.
-
Where is BioCopy headquartered?
BioCopy is headquartered in Basel, Switzerland.
-
What is the size of BioCopy?
BioCopy has 39 total employees.
-
What industry is BioCopy in?
BioCopy’s primary industry is Discovery Tools (Healthcare).
-
Is BioCopy a private or public company?
BioCopy is a Private company.
-
What is BioCopy’s current revenue?
The current revenue for BioCopy is .
-
How much funding has BioCopy raised over time?
BioCopy has raised $24.6M.
-
Who are BioCopy’s investors?
Haute Capital Partners, EASME - EU Executive Agency for SMEs, and The University of Freiburg have invested in BioCopy.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process